Fulcrum Therapeutics Inc
(NAS:FULC)
$
4.79
-0.05 (-1.03%)
Market Cap: 258.37 Mil
Enterprise Value: 12.97 Mil
PE Ratio: 0
PB Ratio: 1.00
GF Score: 50/100 Fulcrum Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 14, 2020 / 05:40PM GMT
Release Date Price:
$16.09
(-2.37%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP
Good afternoon, everyone. Thanks for joining us at the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior biotech analysts here at the bank.
It is my pleasure to introduce our next presenting company, Fulcrum. Presenting for Fulcrum today is President and CEO, Robert Gould. Good afternoon, Robert. Thanks for joining us.
Robert J. Gould
Fulcrum Therapeutics, Inc. - CEO, President & Director
Good afternoon, Tazeen. And it's truly my pleasure to join you today.
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP
So we're looking forward to spending the next 30 minutes with your team. Maybe you can start us off with a quick overview of the company, some of your recent highlights. And then we can go into a little bit more detail about some of your catalysts.
Robert J. Gould
Fulcrum Therapeutics, Inc. - CEO, President & Director
Sure, that would be great. So Fulcrum
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot